CA Patent

CA2731370A1 — Combination of macitentan and a prostacyclin receptor agonist for the treatment of pulmonary hypertension

Assigned to Actelion Pharmaceuticals Ltd · Expires 2010-02-18 · 16y expired

What this patent protects

The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA2731370A1
Jurisdiction
CA
Classification
—
Expires
2010-02-18
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.